Expert Interview
A Second Look: Discussing the the 52-week data from the Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered in people living with obesity.
Ticker(s): AMGN, NVO, LLYInstitution: Columbia University
- Physician-scientist with clinical and research focus in Type 2 Diabetes and related metabolic diseases.
- Board certified in Internal Medicine and fellowship in Endocrinology, Diabetes & Metabolism
- Research focus on the role of developmental pathways in the regulation of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease, and the use of existing therapeutic agents in other scientific areas in novel applications to ameliorate obesity-induced complications including cancer.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
